Epinoma Revenue and Competitors
Estimated Revenue & Valuation
- Epinoma's estimated annual revenue is currently $387.5k per year.
- Epinoma's estimated revenue per employee is $77,500
Employee Data
- Epinoma has 5 Employees.
- Epinoma grew their employee count by -58% last year.
Epinoma's People
Name | Title | Email/Phone |
---|---|---|
1 | Co-Founder | Reveal Email/Phone |
2 | CEO and Co-Founder | Reveal Email/Phone |
3 | Research Scientist | Reveal Email/Phone |
4 | Scientist | Reveal Email/Phone |
5 | Research Associate | Reveal Email/Phone |
Epinoma Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $4.4M | 57 | -8% | $53M | N/A |
#2 | $21.2M | 137 | -26% | $110M | N/A |
#3 | $0.9M | 6 | 0% | N/A | N/A |
#4 | $2.3M | 15 | 15% | N/A | N/A |
#5 | $1.6M | 10 | -17% | N/A | N/A |
#6 | $0.7M | 9 | 50% | N/A | N/A |
#7 | $11.5M | 74 | -12% | N/A | N/A |
#8 | $0.4M | 275 | 10% | $236.7M | N/A |
#9 | $4M | 51 | -74% | $160M | N/A |
#10 | $2.3M | 15 | 15% | N/A | N/A |
What Is Epinoma?
Epinoma is pushing the boundaries of scientific excellence and protein engineering to make the world a healthier place to live. Our first customer will be the 50B market of blood test developers as our technology can improve their product performance. Longer term, we will build a second generation of epigenetic medicines that are safer and more effective for patients. We utilize a protein platform to read and write biological signals called epigenetics. These structural modifications modulate all genes in the human genome and enable us to detect disease earlier and turn disease off.
keywords:N/AN/A
Total Funding
5
Number of Employees
$387.5k
Revenue (est)
-58%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $0.4M | 5 | 150% | N/A |
#2 | $0.8M | 5 | -44% | N/A |
#3 | N/A | 5 | -97% | N/A |
#4 | $0.8M | 5 | -17% | N/A |
#5 | $0.8M | 5 | -29% | N/A |